Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin & Etoposide

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT02978625` - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Not yet recruiting	`NCT04705389` - SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines	N/A
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Completed	`NCT03545334` - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study	N/A
Recruiting	`NCT04260802` - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Phase 1/Phase 2
Recruiting	`NCT04291885` - Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma	Phase 2
Terminated	`NCT02054884` - F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma	Phase 2
Recruiting	`NCT04975152` - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma	Phase 1
Not yet recruiting	`NCT06039033` - Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
Completed	`NCT02514824` - MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT04393753` - Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1	Phase 2
Recruiting	`NCT06056895` - Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma	Phase 2
Recruiting	`NCT03370861` - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Suspended	`NCT04916002` - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer	Phase 2
Recruiting	`NCT03210935` - French National Database of Rare Dermatological Cancers
Active, not recruiting	`NCT04116320` - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04157985` - Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors	Phase 3

NCT number	NCT06086288
Study type	Interventional
Source	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact	Sara Pusceddu
Phone	+390223903251
Email	sara.pusceddu@istitutotumori.mi.it
Status	Not yet recruiting
Phase	Phase 2
Start date	November 2023
Completion date	December 2027

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) — PANDORA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms